For patients with borderline resectable/locally advanced pancreatic ductal adenocarcinoma, preoperative FDG-PET may predict pathologic response to neoadjuvant therapy.
THURSDAY, Sept. 15, 2022 (HealthDay News) For patients with borderline resectable/locally advanced (BR/LA) pancreatic ductal adenocarcinoma (PDAC), preoperative fluorodeoxyglucose positron emission tomography (FDG-PET) may predict pathologic response to neoadjuvant therapy (NAT), according to a study published online Sept. 8 in the Journal of the National Comprehensive Cancer Network. Amro M. Abdelrahman, M.B.B.S., from the
The addition of 18-fluorodeoxyglucose to PET provided significant prognostic benefit in objective assessment of neoadjuvant chemotherapy response among patients with borderline resectable/locally advanced pancreatic cancer.The findings, published in JNCCN — Journal of the National Comprehensive Cancer Network — may help guide decisions on whether to proceed with complex surgery,
According to Mayo Clinic Comprehensive Cancer Center researchers, metabolic imaging (FDG-PET) in combination with traditional treatment response assessment methods can provide clinicians with critical information they need to guide therapy for pancreatic cancer patients. Increasingly impactful nature of research in JNCCN reflected in new high for the journal's Impact Factor, now 12.693. PLYMOUTH MEETING, Pa., Sept. 9, 2022 /PRNewswire/ New research in the September 2022 issue of JNCCN-Journal of the National Comprehensive Cancer Networkfinds the use of positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) tracer adds significant prognostic benefit in objectively assessing neoadjuvant chemotherapy response in borderline resectable/locally advanced pancreatic cancer patients prior to surgery. "We were astonished by how metabolic imaging can now predict outcomes with high accuracy before any surgical intervention," said senior research Mark J. Truty, MD, MS,